Mitsubishi Chemical Group (4188) FY2026 Q3 Earnings Report

Quick View

Executive Summary

For the nine months ended Q3 of the fiscal year ending March 2026, the core business recorded declines in both revenue and profit, but net income increased substantially due to profit from discontinued operations and gains on transfers associated with the restructuring of the business portfolio. Revenue was ¥27372.8B (-8.2% YoY), Operating Income was ¥1133.2B (-22.2%), and Net Income was ¥1572.0B (+47.3%). The greater contraction in Operating Income than in revenue was primarily attributable to deteriorating MMA monomer market conditions and inventory valuation losses in Basic Materials, while the increase in Net Income was driven by the gain on the transfer of Mitsubishi Tanabe Pharma recognized in Q2 and profit from discontinued operations. The full-year forecast for Net Income attributable to owners of the parent was revised downward by ¥780B, from ¥1,250B to ¥470B, due to additional losses associated with the acceleration of structural reforms.

Factors Affecting Results

【Revenue】Revenue was ¥27372.8B, representing a -8.2% YoY decline. Basic Materials & Polymers (-24%) and MMA & Derivatives (-18%) declined significantly due to deteriorating market conditions and weakening demand, while Industrial Gases (+3%) provided support.

【Profit and Loss】Operating Income was ¥1133.2B (-22.2% YoY), representing a contraction exceeding the rate of revenue decline. The Operating Margin was 4.1%, while the difference from the Gross Margin of 28.6% reflects the burden of SG&A expenses at 21.9%. The recognition in Q3 of non-recurring losses associated with the decision to withdraw from the Coke and Carbon Materials Business was a temporary factor. Meanwhile, of Net Income of ¥1572.0B, ¥1,054.3B was attributable to owners of the parent (+77.6%), creating a significant gap with Profit Before Tax of ¥893.4B. This was due to the recognition of ¥948.2B in profit from discontinued operations, including the gain on the transfer of Mitsubishi Tanabe Pharma, and does not represent an improvement in recurring earnings power. In conclusion, the core business experienced declines in both revenue and profit, while consolidated net income increased due to non-recurring factors.

Segment Analysis

Industrial Gases was the largest segment by revenue composition and the primary business. Revenue was ¥9,923B (+3%) and core Operating Income was ¥1,444B (+5%), showing steady performance supported by the use of DX and operational optimization and underpinning consolidated earnings. Specialty Materials recorded a substantial increase in core Operating Income to ¥452B (+35%), supported by strong semiconductor-related demand and the completion of inventory adjustments in display applications. In contrast, MMA & Derivatives recorded a sharp decline in core Operating Income to ¥16B (-95%), primarily due to the decline in MMA monomer market prices. Basic Materials & Polymers posted an Operating Loss of ▲¥29B, but the loss narrowed by ¥91B from the previous year, supported by structural reforms in the carbon business. The gap in profit margins among segments is significant: Industrial Gases and Specialty Materials are driving earnings, while MMA & Derivatives and Basic Materials & Polymers are clear sources of downward pressure.

Key Financial Metrics

ROE was 6.3% on a net assets basis, equivalent to approximately 4.2% based on Net Income attributable to owners of the parent. The Operating Margin was 4.1%, down from approximately 4.9% in the previous year. OCF/Net Income was 1.6x (OCF of ¥2,476.7B ÷ Net Income of ¥1,572.0B), while the ratio based on income attributable to owners of the parent was 2.35x, indicating solid cash support for earnings. Against capital expenditures of ¥2,035.6B, OCF remained at a sufficient level, although ordinary-basis FCF (OCF - capital expenditures) was limited to ¥441.1B. The Equity Ratio was 31.8%, improving from 29.5% in the previous year, indicating a modest improvement in financial soundness.

Cash Flow Analysis

OCF was ¥2,476.7B, down -27.8% YoY, but cash generation remained solid relative to Net Income. Investing CF was an inflow of ¥1,231.3B, as proceeds from the sale of subsidiaries of ¥5,167.8B exceeded capital expenditures of ¥2,035.6B. Financing CF was an outflow of ¥3,472.6B, primarily due to dividend payments of ¥445.1B, share repurchases of ¥500.2B, and a net decrease in borrowings. FCF (OCF + investing CF) was ¥3,708.0B, but underlying FCF excluding proceeds from asset sales was limited to ¥441.1B. Cash generation was strong on a reported basis, but at a standard level when one-off disposal proceeds are excluded.

Earnings Quality

There was a significant gap between Operating Income of ¥1,133.2B, a recurring earnings indicator, and Net Income of ¥1,572.0B, which includes discontinued operations. The primary cause of the difference was ¥948.2B in profit from discontinued operations, including the gain on the transfer of Mitsubishi Tanabe Pharma, which should be treated as a temporary factor. Net Income of ¥1,572.0B, after deducting income taxes and other taxes of ¥269.6B from Profit Before Tax of ¥893.4B, exceeded the earnings level from continuing operations alone; therefore, caution is warranted when assessing recurring earning power. OCF of ¥2,476.7B exceeded Net Income, and from an accruals perspective, there is no significant concern regarding earnings quality.

Earnings Forecast and Guidance

Progress toward the full-year Revenue forecast of ¥36,720B was 74.5%, broadly in line with the standard 75%. Progress toward the full-year Operating Income forecast of ¥700.0B was 161.9%, substantially ahead, because the full-year forecast itself remains at a conservative level incorporating weak market conditions in the second half and structural reform costs. The full-year forecast for Net Income attributable to owners of the parent was revised downward by ¥780B, from ¥1,250B to ¥470.0B, due to the recognition of additional losses associated with the acceleration of structural reforms. The full-year core Operating Income forecast of ¥2,500B remains unchanged.

Shareholder Returns

The dividend remains unchanged at ¥16 per share for the interim dividend and an expected ¥16 per share for the year-end dividend, for an annual total of ¥32 per share. The Payout Ratio based on Net Income attributable to owners of the parent is approximately 21.9% (dividend payments of ¥445.1B ÷ Net Income of ¥1,572.0B), and is expected to rise to approximately 93.3% against the full-year forecast profit of ¥470.0B. The Total Return Ratio, including share repurchases of ¥500.2B, is approximately 89.7%, calculated as total dividends and share repurchases of ¥945.3B divided by Net Income attributable to owners of the parent of ¥1,054.3B. Dividend sustainability will depend on the pace of recovery in core business earnings and the ability to secure cash generation independent of asset sale proceeds.

Catalysts

【Short Term】The timing and scale of additional structural reform costs associated with the withdrawal from the Coke and Carbon Materials Business, as well as trends in MMA monomer and Basic Materials market conditions in Q4.

【Long Term】Progress in portfolio reform under the Medium-Term Management Plan 2029 and the strengthening of the earnings base of Industrial Gases and Specialty Materials.

Industry Benchmark (Reference; Compiled by the Company)

Profitability and Returns

The Operating Margin is significantly below the industry median, placing profitability at a low level within the industry.

Growth and Capital Efficiency

The Revenue Growth Rate is significantly below the industry median, placing top-line growth among the weaker performers in the industry.

※Source: Compiled by the Company

Risk Factors

1. Market Condition Volatility Risk: Due to the decline in MMA monomer market conditions, core Operating Income in MMA & Derivatives declined -95% YoY. Basic Materials & Polymers was also significantly affected by deteriorating market conditions, with revenue down -24%; the pace of future recovery in supply and demand will directly affect results.

2. Working Capital Efficiency Risk: The turnover efficiency of accounts receivable and inventories is trending downward, with factors such as a ¥64.3B increase in inventories weighing on OCF. Delays in adjusting supply and demand could lead to inventory valuation loss risk.

3. One-Off Cost Risk Associated with Business Restructuring: The decision to withdraw from the Coke and Carbon Materials Business resulted in the recognition of non-recurring losses in Q3, and the full-year forecast for Net Income attributable to owners of the parent was revised downward by ¥780B. Additional losses may be recognized depending on the progress of structural reforms.

Key Earnings Highlights

1. Core business profitability, as measured by an Operating Margin of 4.1%, is below the industry median of 8.6%. The structure is clear: Industrial Gases and Specialty Materials support earnings, while deteriorating market conditions in MMA and Basic Materials & Polymers weigh on overall results.

2. The substantial increase in Net Income was attributable to profit from discontinued operations and gains on transfers and must be assessed separately from the declining trend in Operating Income. The full-year forecast was also significantly revised downward due to non-recurring losses.

3. The annual dividend remains unchanged at ¥32 per share, while the Total Return Ratio including share repurchases is high at approximately 89.7%. The sustainability of the Payout Ratio and shareholder returns will depend on the pace of recovery in core business earnings.

Theoretical Share Price (Reference Value)

Sensitivity: ¥1,114–¥1,176 at ±1% for the cost of equity, and ¥1,137–¥1,149 at ±0.1 for ω.

Notes:

• Because progress of Net Income toward the full-year forecast (224%) exceeds the standard level (75%), forecast EPS has been adjusted upward within a maximum range of +10% (because companies progressing ahead of their forecasts tend to exceed those forecasts; the adjustment may be excessive for businesses with strong seasonality).
• Because forecast ROE is below the cost of equity, the theoretical value is below Book Value Per Share.
• The ratio of goodwill to net assets is high, and the assumptions would change significantly if impairment occurred.
• Net assets at the end of the quarter are used (there is a timing difference relative to the full-year forecast).

(Calculation model: Residual Income Model (Ohlson-type; explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated through AI-integrated analysis of XBRL earnings summary data and PDF earnings presentation materials. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting a professional as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2026 Q3 performance was operationally weaker, while reported profit attributable to owners rose sharply because discontinued operations dominated bottom-line earnings. Revenue declined 8.2% year on year to ¥2,737.3bn and operating income fell 22.2% to ¥113.3bn. The operating margin compressed by 70bp to 4.1% from 4.9% in the prior-year period. Gross profit was broadly flat at ¥782.4bn despite lower sales, lifting gross margin by 250bp to 28.6% from 26.2%. However, SG&A increased 1.5% to ¥600.3bn, creating negative operating leverage as revenue contracted. Profit before tax declined 23.9% to ¥89.3bn, consistent with the deterioration in core operating profit. Finance costs of ¥30.7bn exceeded finance income of ¥6.7bn, leaving the interest burden at 0.788x; approximately 21% of EBIT was absorbed below the operating line. Profit attributable to owners increased 77.6% to ¥105.4bn and EPS rose to ¥76.70. This headline increase was principally supported by ¥948.2bn of profit from discontinued operations, while profit from continuing operations was only ¥623.8bn. Accordingly, the 3.9% net margin and 5.7% annualized ROE overstate the earning power of the continuing portfolio. Operating cash flow of ¥247.7bn was 2.35x profit attributable to owners, indicating strong cash realization in the reported period. Cash conversion nevertheless declined year on year, with operating cash flow down 27.8% from ¥342.8bn. Conventional operating cash flow less capital expenditure was positive at ¥44.1bn, but only modest relative to the ¥203.6bn capital-investment program. Reported free cash flow of ¥370.8bn benefited substantially from net investing inflows, notably ¥516.8bn in proceeds from sales of subsidiaries. The full-year operating-income forecast is ¥70.0bn, so Q3 cumulative operating income already represents 161.9% of guidance; this strongly implies a large Q4 loss, disposal-related deconsolidation effects, or a conservatively maintained forecast. The full-year profit-attributable-to-owners forecast of ¥47.0bn is also only 44.6% of Q3 cumulative profit attributable to owners, reinforcing that Q3 reported earnings are not an appropriate run-rate. The central forward issue is whether portfolio restructuring can translate the improved gross margin into sustainably higher continuing operating profit while reducing leverage and working-capital intensity.

Profitability Analysis

The annualized DuPont decomposition is net profit margin of 3.9% × asset turnover of 0.627x × financial leverage of 2.35x, producing annualized ROE of 5.7%. This ROE is below the 8% level generally associated with adequate capital efficiency, and the most important limitation is profitability rather than balance-sheet leverage. The 70bp decline in operating margin to 4.1% is particularly material because it falls below the 5% operating-efficiency threshold. Revenue decreased ¥245.4bn year on year, whereas SG&A rose ¥8.6bn, demonstrating adverse operating leverage and insufficient cost flexibility. Gross margin improved 250bp to 28.6%, indicating that the principal pressure was not at the gross-profit level but arose from overhead absorption and operating expenses. EBIT margin was 4.1%, while the interest burden was 0.788x, leaving only ¥89.3bn of pre-tax income from ¥113.3bn of EBIT. The tax burden of 1.180x is atypical because reported net income includes a large contribution from discontinued operations, so it should not be interpreted as a recurring tax advantage. Continuing operations generated ¥62.4bn of profit, whereas discontinued operations generated ¥94.8bn; portfolio actions rather than the retained operations explain the strong increase in profit attributable to owners. ROIC of 4.3% is below 5%, which indicates that returns on the group’s operating capital remain weak for a capital-intensive chemicals manufacturer. The improvement in gross margin may be constructive if pricing, product mix, and raw-material spreads hold, but the decline in revenue and operating income means sustainability has not yet been established. Goodwill of ¥880.2bn, equal to 35.5% of total equity, increases the importance of restoring returns at acquired businesses because future impairment would directly pressure equity and earnings.

Growth Assessment

Top-line momentum was negative, with Q3 cumulative revenue declining 8.2% year on year to ¥2,737.3bn. Operating income declined more rapidly than sales, down 22.2%, confirming that current earnings growth is not being generated by the continuing operating base. Gross profit increased ¥1.7bn despite the revenue decline, and the gross-margin expansion to 28.6% suggests some resilience in product mix or input-cost pass-through. That benefit was more than offset by SG&A growth, which reduced operating income by ¥32.2bn. Profit attributable to owners grew 77.6%, but this was not organic growth: discontinued operations accounted for ¥94.8bn of profit and exceeded reported profit attributable to owners of ¥105.4bn. The full-year sales forecast of ¥3,672.0bn implies Q3 sales progress of 74.5%, broadly in line with the standard 75% Q3 benchmark. In contrast, operating-income progress is 161.9% against the ¥70.0bn full-year forecast, a deviation of 86.9 percentage points above the standard benchmark. Profit-attributable-to-owners progress is 224.3% against the ¥47.0bn forecast, a deviation of 149.3 percentage points above the standard benchmark. The mismatch between Q3 results and full-year guidance indicates that portfolio changes and discontinued operations are likely to make Q4 reported earnings materially weaker than the cumulative result suggests. The low 2/10 consistency score further supports a cautious interpretation of period earnings and highlights volatility in the earnings base.

Financial Health

The balance sheet strengthened year on year as total equity rose ¥1,973.8bn to ¥2,481.8bn and the equity ratio improved 230bp to 31.8%. Total liabilities declined ¥271.8bn to ¥3,339.7bn, while total assets decreased ¥73.1bn to ¥5,821.5bn. Current assets of ¥2,054.4bn and implied current liabilities of ¥1,358.2bn produce a current ratio of approximately 1.51x, above 1.0x and consistent with adequate near-term balance-sheet coverage. Cash and cash equivalents of ¥366.5bn, trade receivables of ¥678.4bn, and other current financial assets of ¥202.4bn provide meaningful liquidity support. However, the approximate quick ratio is 0.92x, below 1.0x, so liquidity depends partly on inventory realization. Current bonds and borrowings total ¥406.9bn against current assets of ¥2,054.4bn, limiting immediate maturity-mismatch risk. Non-current bonds and borrowings of ¥1,496.6bn remain substantial, although they declined ¥116.3bn year on year; current borrowings also declined ¥21.2bn. The reported debt-to-equity ratio is 1.35x, below the 2.0x aggressive-leverage warning level but still meaningful for a business generating a 4.1% EBIT margin. EBIT covered finance costs by approximately 3.7x, which is above the 3x concern threshold but below the 5x level associated with strong interest protection. Net defined-benefit liabilities of ¥103.1bn and total provisions of ¥40.3bn are additional fixed claims to monitor. Goodwill represents 15.1% of assets and 35.5% of equity, an elevated but not warning-level concentration; preservation of acquired-business value remains important to capital resilience.

Notable B/S Changes

Property, plant and equipment: +¥86.3bn (+4.3%) to ¥2,099.1bn — continued capital intensity and investment in the retained manufacturing asset base. Goodwill: +¥52.6bn (+6.4%) to ¥880.2bn — absolute increase exceeds ¥50bn and lifts goodwill to 35.5% of equity; acquired-business performance remains important for impairment risk. Intangible assets: -¥69.1bn (-15.6%) to ¥372.9bn — amortization, disposals, or portfolio restructuring reduced the intangible-asset base. Inventories: -¥83.9bn (-11.0%) to ¥675.6bn — balance-sheet reduction is positive, although annualized inventory days remain elevated at 95 days. Trade receivables: -¥86.4bn (-11.3%) to ¥678.4bn — lower receivable balances support capital release, but annualized DSO remains high at 68 days. Non-current bonds and borrowings: -¥116.3bn (-7.2%) to ¥1,496.6bn — deleveraging improves balance-sheet resilience and should support interest-cost control. Other current financial assets: +¥136.3bn (+206.2%) to ¥202.4bn — liquidity composition shifted toward financial assets, supporting near-term funding flexibility. Total equity: +¥197.4bn (+8.6%) to ¥2,481.8bn — capitalization improved and the equity ratio increased to 31.8% from 29.5%. Non-controlling interests: +¥87.5bn (+16.1%) to ¥631.5bn — a larger share of group equity and comprehensive income is attributable to minority shareholders.

Cash Flow Quality

Cash earnings quality was strong on the reported basis: operating cash flow was ¥247.7bn, equal to 2.35x profit attributable to owners of ¥105.4bn. The accruals ratio was negative 2.4%, which is consistent with cash conversion rather than aggressive accrual-led earnings. This positive assessment must be tempered by the composition of accounting income, as discontinued operations materially elevated reported profit while operating cash flow declined 27.8% year on year. Working-capital movements were a net cash outflow: receivables consumed ¥7.9bn, inventories consumed ¥6.4bn, payables supplied ¥4.9bn, and other working-capital changes consumed ¥86.8bn. Receivable days were 68 days, above the 60-day warning threshold, indicating slower collections and greater cash tied up in customer balances. Inventory days were 95 days, above both the 90-day and 60-day warning thresholds, creating elevated inventory carrying, pricing, and obsolescence risk for a cyclical chemical manufacturer. Inventory nevertheless declined ¥83.9bn year on year to ¥675.6bn, providing some evidence of balance-sheet reduction rather than inventory accumulation. Capital expenditure was ¥203.6bn, equal to 7.4% of Q3 cumulative revenue and at the upper end of the typical manufacturing range. Conventional free cash flow, defined as operating cash flow less capital expenditure, was positive at ¥44.1bn. The reported ¥370.8bn free cash flow includes positive investing cash flow of ¥123.1bn, driven principally by ¥516.8bn of proceeds from sales of subsidiaries, and should not be treated as recurring free cash generation. Financing cash outflow of ¥347.3bn included ¥99.3bn of long-term debt repayments, ¥113.2bn of net short-term borrowing reduction, ¥50.0bn of share repurchases, and ¥44.5bn of cash dividends. This deleveraging and shareholder return were supported by restructuring-related cash inflows, reducing the extent to which they demonstrate normalized recurring cash capacity.

Dividend Sustainability

The indicated full-year dividend is ¥32.00 per share, comprising the ¥16.00 interim dividend and a ¥16.00 year-end amount implied by the forecast. Against forecast EPS of ¥34.29, the forward dividend payout ratio is approximately 93.3%, materially above the sub-60% benchmark for a comfortably sustainable ordinary dividend payout. The historical calculated Q2-only payout ratio was 21.9% using Q3 cumulative profit attributable to owners, but that denominator was inflated by discontinued-operation profit and therefore understates forward payout pressure. Cash dividends paid were ¥44.5bn during Q3, while dividends recognized in equity were ¥65.7bn. Share repurchases totaled ¥50.0bn. Using dividends recognized in equity plus buybacks, the total return ratio was approximately 109.7% of profit attributable to owners, above 100% and therefore not fully covered by reported owner earnings. Using cash dividends paid plus buybacks, cash shareholder distributions were ¥94.5bn, equivalent to roughly 89.7% of profit attributable to owners. Conventional free cash flow of ¥44.1bn did not cover these cash shareholder distributions, whereas reported free cash flow including subsidiary-disposal proceeds did. Dividend continuity therefore depends on management’s confidence in normalized post-restructuring cash generation, balance-sheet capacity, and the realization of portfolio-sale proceeds rather than on Q3 continuing operating earnings alone. The strengthened equity ratio and reduction in debt provide some support, but the forecast payout leaves limited earnings retention if the low operating-profit outlook persists.

Risk Assessment

Business risks include High priority — Core operating profitability: the EBIT margin fell to 4.1%, below the 5% efficiency threshold, and operating income declined 22.2% despite a 250bp gross-margin improvement. This indicates that overhead absorption and cost control remain critical to restoring profitability., High priority — Demand, pricing, and product-mix risk: revenue fell 8.2% in a cyclical chemical manufacturing business. A further weakening in industrial demand or chemical spreads could erode the recently improved 28.6% gross margin., High priority — Working-capital risk: receivable days of 68 and inventory days of 95 exceed warning levels. Slow collections and elevated inventory can reduce cash generation, necessitate price reductions, and increase inventory valuation risk., Medium priority — Portfolio-execution risk: discontinued operations generated ¥94.8bn of profit, while ¥516.8bn of proceeds from sales of subsidiaries supported investing cash flow. The investment case depends on replacing disposed earnings with stronger returns from the retained portfolio., Medium priority — Goodwill value-retention risk: goodwill is ¥880.2bn, or 35.5% of equity. This is elevated relative to the 30% healthy benchmark, making acquired-business performance and impairment testing material..

Financial risks include High priority — Interest-service risk: the 0.788x interest burden means finance costs consumed about 21% of EBIT. EBIT-to-finance-cost coverage of approximately 3.7x is adequate but below the 5x strong-coverage benchmark., Medium priority — Leverage and liquidity risk: reported debt-to-equity is 1.35x and the quick ratio is approximately 0.92x. While the current ratio of about 1.51x is healthy, liquidity is partly dependent on inventory monetization., Medium priority — Distribution-coverage risk: the forward dividend payout ratio is approximately 93.3%, and the total return ratio including ¥50.0bn of repurchases was about 109.7% of owner earnings., Medium priority — Capital-return risk: ROIC of 4.3% is below 5%, suggesting returns may remain below the cost of capital absent a significant recovery in operating earnings..

Key concerns include Reported net-income growth is not representative of recurring operations because discontinued operations accounted for ¥94.8bn of profit., The full-year ¥70.0bn operating-income forecast is far below the ¥113.3bn earned through Q3, indicating expected Q4 weakness or major portfolio-related effects., SG&A increased 1.5% while revenue declined 8.2%, demonstrating unfavorable operating leverage., The chemical industry remains exposed to feedstock and energy-price volatility, global supply additions, customer-industry cycles, environmental regulation, and plant reliability risks..

Investment Implications

Key takeaways include Gross-margin expansion to 28.6% is a favorable signal, but it has not translated into operating-profit growth because SG&A rose while sales declined., Q3 profit attributable to owners of ¥105.4bn and EPS of ¥76.70 are heavily influenced by discontinued operations and are not a recurring earnings run-rate., Annualized ROE of 5.7% and ROIC of 4.3% remain below common capital-efficiency thresholds., Operating cash conversion is strong, but recurring free cash flow after capital expenditure was only ¥44.1bn; reported free cash flow benefited from subsidiary-sale proceeds., Balance-sheet capitalization improved, with the equity ratio rising to 31.8% and borrowings declining, though interest coverage and goodwill concentration still require monitoring., The forward ¥32.00 DPS implies a high approximately 93.3% payout ratio on forecast EPS, making normalized cash generation central to dividend durability..

Metrics to watch include Operating margin and SG&A-to-sales ratio, particularly whether the 4.1% EBIT margin can recover above 5%., Continuing-operation profit relative to the full-year ¥70.0bn operating-income forecast., Receivable days, inventory days, and cash conversion as restructuring progresses., EBIT-to-finance-cost coverage and reported debt-to-equity ratio., Goodwill relative to equity and any impairment indicators at acquired businesses., Conventional free cash flow after capital expenditure, rather than disposal-supported reported free cash flow., The relationship between the ¥32.00 DPS, forecast EPS of ¥34.29, and future share-repurchase activity..

Regarding relative positioning, The group combines a strengthened equity base and favorable gross-margin movement with below-threshold operating and capital efficiency. Relative positioning is therefore driven less by headline Q3 net-income growth and more by the ability of the retained chemicals portfolio to convert improved gross profit into recurring EBIT, reduce elevated working-capital days, and sustain distributions without reliance on portfolio-disposal proceeds.